Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q5T653
UPID:
RM02_HUMAN
Alternative names:
39S ribosomal protein L2, mitochondrial
Alternative UPACC:
Q5T653; B2RC56; Q8WUL1; Q96Q56; Q9Y311
Background:
The Large ribosomal subunit protein uL2m, also known as 39S ribosomal protein L2, mitochondrial, plays a crucial role in protein synthesis within mitochondria. Its involvement in the assembly of the mitochondrial ribosome underscores its importance in cellular energy production and overall mitochondrial function.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein uL2m could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis makes it a key target for research aimed at addressing mitochondrial disorders.